An association between oral microbiota and cognitive performance in schizophrenia has been reported by researchers at Science Tokyo. By analyzing saliva samples and cognitive test scores from patients ...

In fall 2024, xanomeline trospium chloride (XT) was approved by the U.S. Food and Drug Administration for the treatment of adults with schizophrenia. In an earlier post, we reviewed evidence that this ...

Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of cognitive impairment, with a notably higher likelihood of developing non-amnestic mild cognitive impairment.

A new study reveals that COVID-19 patients suffer from significant, long-term cognitive deficits even a year after hospitalization, with brain injury markers and reduced brain volume suggesting immune ...